The Medicines Company announced that the Food and Drug Administration (FDA) has approved their supplemental new drug application (sNDA) for a new formulation of Minocin (minocycline) for Injection.

Minocin for Injection is a tetracycline derivative indicated for the treatment of infections due to susceptible strains of designated microorganisms, including Acinetobacter species bacteria.

The FDA granted Qualified Infectious Disease Product (QIDP) designation to the new formulation of Minocin for Injection; the designation would qualify Minocin for Injection for priority review and five years of marketing exclusivity upon an approval of the additional potential indications.

RELATED: Multidrug-Resistant Intestinal Illness Spreading in U.S.

Minocin for Injection will be available in 100mg strength vials and is currently available in 50mg, 75mg, and 100mg pellet-filled caps.

For more information call (800) 388-1189 or visit